牛牛AI助理已提取核心訊息
On December 31, 2023, Armistice Capital, LLC, an investment adviser, and its managing member Steven Boyd filed an amended Schedule 13G/A with the SEC, indicating a shared voting and dispositive power over 24,951 American Depositary Shares of Biodexa Pharmaceuticals Plc. This represents 0.94% of the class, based on 2,644,468 shares outstanding as of December 21, 2023. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, which applies to certain institutional investment managers. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., which directly holds the shares. However, the Master Fund disclaims beneficial ownership of the securities due to its Investment Management Agreement with Armistice Capital. The filing also notes that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Biodexa Pharmaceuticals.
On December 31, 2023, Armistice Capital, LLC, an investment adviser, and its managing member Steven Boyd filed an amended Schedule 13G/A with the SEC, indicating a shared voting and dispositive power over 24,951 American Depositary Shares of Biodexa Pharmaceuticals Plc. This represents 0.94% of the class, based on 2,644,468 shares outstanding as of December 21, 2023. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, which applies to certain institutional investment managers. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., which directly holds the shares. However, the Master Fund disclaims beneficial ownership of the securities due to its Investment Management Agreement with Armistice Capital. The filing also notes that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Biodexa Pharmaceuticals.
2023年12月31日，投資顧問停戰資本有限責任公司及其管理成員史蒂芬·博伊德向美國證券交易委員會提交了經修訂的附表13G/A，表示對Biodexa Pharmicals Plc的24,951股美國存托股票擁有共同的投票權和處置權。根據截至2023年12月21日已發行的2,644,468股股票，這佔該類別的0.94％。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，該規則適用於某些機構投資經理。停戰資本是停戰資本總基金有限公司的投資經理，該公司直接持有股份。但是，由於與停戰資本簽訂了投資管理協議，主基金宣佈放棄對證券的實益所有權。該文件還指出，這些證券是在正常業務過程中收購的，不是爲了改變或影響Biodexa Pharmicals的控制權。
2023年12月31日，投資顧問停戰資本有限責任公司及其管理成員史蒂芬·博伊德向美國證券交易委員會提交了經修訂的附表13G/A，表示對Biodexa Pharmicals Plc的24,951股美國存托股票擁有共同的投票權和處置權。根據截至2023年12月21日已發行的2,644,468股股票，這佔該類別的0.94％。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，該規則適用於某些機構投資經理。停戰資本是停戰資本總基金有限公司的投資經理，該公司直接持有股份。但是，由於與停戰資本簽訂了投資管理協議，主基金宣佈放棄對證券的實益所有權。該文件還指出，這些證券是在正常業務過程中收購的，不是爲了改變或影響Biodexa Pharmicals的控制權。
有用
沒用